Evidence map›Paper›PMID 28554332›Full record

ArticleGenome medicine2017

Genomic diagnosis for children with intellectual disability and/or developmental delay.

Kevin M Bowling, Michelle L Thompson, Michelle D Amaral, Candice R Finnila, Susan M Hiatt, Krysta L Engel, J Nicholas Cochran, Kyle B Brothers, Kelly M East, David E Gray and 12 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 1 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 1 synthesis or guideline pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Determinants of DNA-sequence-based Diagnostic Yield in the CSER Consortium.medRxiv : the preprint server for health sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Longitudinal Characterization of GiantResearch (Washington, D.C.) · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Kevin M BowlingHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Michelle L ThompsonHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Michelle D AmaralHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Candice R FinnilaHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Susan M HiattHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Krysta L EngelHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
J Nicholas CochranHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Kyle B BrothersUniversity of Louisville, Louisville, KY, USA.
Kelly M EastHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
David E GrayHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Whitley V KelleyHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Neil E LambHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Edward J LoseUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Carla A RichUniversity of Louisville, Louisville, KY, USA.
Shirley SimmonsUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Jana S WhittleHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Benjamin T WeaverHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Amy S NesmithHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Richard M MyersHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
Gregory S BarshHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
E Martina BebinUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Gregory M CooperHudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA. gcooper@hudsonalpha.org.
HudsonAlpha Institute for Biotechnology · USUniversity of Alabama at Birmingham · USUniversity of Louisville · USUniversity of Alabama in Huntsville · US

Funding

Genomic Diagnosis in Children with Developmental DelayUM1HG007301 · NHGRI · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI COOPER, GREGORY MICHAEL, MYERS, RICHARD M · 2013 to 2016
$7.5M
Integrative interpretation of the organismal consequences of non-coding variationR01CA197139 · NCI · UNIVERSITY OF WASHINGTON · PI COOPER, GREGORY MICHAEL, SHENDURE, JAY ASHOK · 2015 to 2017
$1.9M
NCI NIH HHS R01 CA197139NHGRI NIH HHS UM1 HG007301
6 · The paper itself

Abstract

backgroundDevelopmental disabilities have diverse genetic causes that must be identified to facilitate precise diagnoses. We describe genomic data from 371 affected individuals, 309 of which were sequenced as proband-parent trios.

methodsWhole-exome sequences (WES) were generated for 365 individuals (127 affected) and whole-genome sequences (WGS) were generated for 612 individuals (244 affected).

resultsPathogenic or likely pathogenic variants were found in 100 individuals (27%), with variants of uncertain significance in an additional 42 (11.3%). We found that a family history of neurological disease, especially the presence of an affected first-degree relative, reduces the pathogenic/likely pathogenic variant identification rate, reflecting both the disease relevance and ease of interpretation of de novo variants. We also found that improvements to genetic knowledge facilitated interpretation changes in many cases. Through systematic reanalyses, we have thus far reclassified 15 variants, with 11.3% of families who initially were found to harbor a VUS and 4.7% of families with a negative result eventually found to harbor a pathogenic or likely pathogenic variant. To further such progress, the data described here are being shared through ClinVar, GeneMatcher, and dbGaP.

conclusionsOur data strongly support the value of large-scale sequencing, especially WGS within proband-parent trios, as both an effective first-choice diagnostic tool and means to advance clinical and research progress related to pediatric neurological disease.

Indexed as

DNA Copy Number VariationsMutationAdolescentAdultChildChild, PreschoolDevelopmental DisabilitiesExomeFemaleGenomicsHumansInfantIntellectual DisabilityMaleSequence Analysis, DNAYoung AdultClinical sequencingCSERDe novoDevelopmental delayIntellectual disability

Identifiers

PMID28554332
PMCPMC5448144
OpenAlexW2951097328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.